Glucocorticoid receptor-mediated transcriptional activation of S100P gene coding for cancer-related calcium-binding protein

Journal of Cellular Biochemistry

Volumn 112, Issue 11, 2011, Pages 3373-3384

  Tothova, Veronika ^a   Isola, Jorma ^b   Parkkila, Seppo ^b   Kopacek, Juraj ^a   Pastorek, Jaromir ^a   Pastorekova, Silvia ^a   Gibadulinova, Adriana ^a  

^a INSTITUTE OF VIROLOGY   (Slovakia)

^b TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

CANCER; DEXAMETHASONE; GLUCOCORTICOID RECEPTOR; MAPK PATHWAY; S100P PROMOTER; TRANSCRIPTION

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; CALCIUM BINDING PROTEIN; DEXAMETHASONE; GLUCOCORTICOID RECEPTOR; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN S 100;

ARTICLE; CANCER CELL; CONTROLLED STUDY; ENZYME INHIBITION; FEMALE; GENETIC CODE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RNA TRANSPORT; SIGNAL TRANSDUCTION; TRANSACTIVATION; TRANSCRIPTION REGULATION; TUMOR GENE;

BASE SEQUENCE; BLOTTING, WESTERN; CALCIUM-BINDING PROTEINS; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASES; CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; DEXAMETHASONE; DNA PRIMERS; FLAVONOIDS; HUMANS; NEOPLASM PROTEINS; NEOPLASMS; PROMOTER REGIONS, GENETIC; PROTEIN KINASE INHIBITORS; RECEPTORS, GLUCOCORTICOID; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TRANSCRIPTIONAL ACTIVATION;

EID: 80054967255     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.23268     Document Type: Article

References (49)

1. Adams CM,. 2007. Role of the transcription factor ATF4 in the anabolic actions of insulin and the anti-anabolic actions of glucocorticoids. J Biol Chem 282: 16744-16753. (Pubitemid 47093239)
2. Arancibia S, Benitez D, Nunez LE, Jewell CM, Langjhar P, Candia E, Zapata-Torres G, Cidlowski JA, Gonzalez MJ, Hermoso MA,. 2011. Phosphatidylinositol 3-kinase interacts with the glucocorticoid receptor upon TLR2 activation. J Cell Mol Med 15: 339-349.
3. Arumugam T, Simeone DM, Schmidt AM, Logsdon CD,. 2004. S100P stimulates cell proliferation and survival via receptor for activated glycation end products (RAGE). J Biol Chem 279: 5059-5065. (Pubitemid 38220521)
4. Arumugam T, Simeone DM, Van Golen K, Logsdon CD,. 2005. S100P promotes pancreatic cancer growth, survival, and invasion. Clin Cancer Res 11: 5356-5364. (Pubitemid 41060808)
5. Basu GD, Azorsa DO, Kiefer JA, Rojas AM, Tuzmen S, Barrett MT, Trent JM, Kallioniemi O, Mousses S,. 2008. Functional evidence implicating S100P in prostate cancer progression. Int J Cancer 123: 330-339. (Pubitemid 351842017)
6. Becker T, Gerke V, Kube E, Weber K,. 1992. S100P, a novel Ca(2+)-binding protein from human placenta. cDNA cloning, recombinant protein expression and Ca2+ binding properties. Eur J Biochem 207: 541-547.
7. Belova L, Delgado B, Kocherginsky M, Melhem A, Olopade OI, Conzen SD,. 2009. Glucocorticoid receptor expression in breast cancer associates with older patient age. Breast Cancer Res Treat 116: 441-447.
8. Bertram J, Palfner K, Hiddemann W, Kneba M,. 1998. Elevated expression of S100P, CAPL and MAGE 3 in doxorubicin-resistant cell lines: Comparison of mRNA differential display reverse transcription-polymerase chain reaction and subtractive suppressive hybridization for the analysis of differential gene expression. Anticancer Drugs 9: 311-317. (Pubitemid 28241820)
9. Casals-Casas C, Alvarez E, Serra M, de la Torre C, Farrera C, Sanchez-Tillo E, Caelles C, Lloberas J, Celada A,. 2009. CREB and AP-1 activation regulates MKP-1 induction by LPS or M-CSF and their kinetics correlate with macrophage activation versus proliferation. Eur J Immunol 39: 1902-1913.
10. Donato R,. 2003. Intracellular and extracellular roles of S100 proteins. Microsc Res Tech 60: 540-551.
11. Dougherty MK, Muller J, Ritt DA, Zhou M, Zhou XZ, Copeland TD, Conrads TP, Veenstra TD, Lu KP, Morrison DK,. 2005. Regulation of Raf-1 by direct feedback phosphorylation. Mol Cell 17: 215-224. (Pubitemid 40138617)
12. Dowen SE, Crnogorac-Jurcevic T,. 2006. S100 proteins in cancer. Calcium Binding Proteins 1: 143-149.
13. Favata MF, Horiuchi KY, Manos EJ, Daulerio AJ, Stradley DA, Feeser WS, Van Dyk DE, Pitts WJ, Earl RA, Hobbs F, Copeland RA, Magolda RL, Scherle PA, Trzaskos JM,. 1998. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem 273: 18623-18632. (Pubitemid 28334795)
14. Frost JA, Geppert TD, Cobb MH, Feramisco JR,. 1994. A requirement for extracellular signal-regulated kinase (ERK) function in the activation of AP-1 by Ha-Ras, phorbol 12-myristate 13-acetate, and serum. Proc Natl Acad Sci USA 91: 3844-3848. (Pubitemid 24139528)
15. Fuentes MK, Nigavekar SS, Arumugam T, Logsdon CD, Schmidt AM, Park JC, Huang EH,. 2007. RAGE activation by S100P in colon cancer stimulates growth, migration, and cell signaling pathways. Dis Colon Rectum 50: 1230-1240. (Pubitemid 47087458)
16. Gibadulinova A, Oveckova I, Parkkila S, Pastorekova S, Pastorek J,. 2008. Key promoter elements involved in transcriptional activation of the cancer-related gene coding for S100P calcium-binding protein. Oncol Rep 20: 391-396.
17. Hamada S, Satoh K, Hirota M, Fujibuchi W, Kanno A, Umino J, Ito H, Satoh A, Kikuta K, Kume K, Masamune A, Shimosegawa T,. 2009. Expression of the calcium-binding protein S100P is regulated by bone morphogenetic protein in pancreatic duct epithelial cell lines. Cancer Sci 100: 103-110.
18. Heizmann CW, Cox JA,. 1998. New perspectives on S100 proteins: A multi-functional Ca(2+)-, Zn(2+)- and Cu(2+)-binding protein family. Biometals 11: 383-397. (Pubitemid 29121544)
19. Heizmann CW, Fritz G, Schafer BW,. 2002. S100 proteins: Structure, functions and pathology. Front Biosci 7: d1356-d1368.
20. Herr I, Pfitzenmaier J,. 2006. Glucocorticoid use in prostate cancer and other solid tumours: Implications for effectiveness of cytotoxic treatment and metastases. Lancet Oncol 7: 425-430.
21. Jiang F, Shults K, Flye L, Hashimoto Y, Van Der Meer R, Xie J, Kravtsov V, Price J, Head DR, Briggs RC,. 2005. S100P is selectively upregulated in tumor cell lines challenged with DNA cross-linking agents. Leuk Res 29: 1181-1190. (Pubitemid 41169235)
22. Kassel O, Sancono A, Kratzschmar J, Kreft B, Stassen M, Cato AC,. 2001. Glucocorticoids inhibit MAP kinase via increased expression and decreased degradation of MKP-1. EMBO J 20: 7108-7116. (Pubitemid 34062302)
23. Kino T, Manoli I, Kelkar S, Wang Y, Su YA, Chrousos GP,. 2009. Glucocorticoid receptor (GR) beta has intrinsic, GRalpha-independent transcriptional activity. Biochem Biophys Res Commun 381: 671-675.
24. Koltzscher M, Neumann C, Konig S, Gerke V,. 2003. Ca2+-dependent binding and activation of dormant ezrin by dimeric S100P. Mol Biol Cell 14: 2372-2384. (Pubitemid 36724327)
25. Konig H, Ponta H, Rahmsdorf HJ, Herrlich P,. 1992. Interference between pathway-specific transcription factors: Glucocorticoids antagonize phorbol ester-induced AP-1 activity without altering AP-1 site occupation in vivo. EMBO J 11: 2241-2246.
26. Kumar R, Thompson EB,. 2005. Gene regulation by the glucocorticoid receptor: Structure:Function relationship. J Steroid Biochem Mol Biol 94: 383-394. (Pubitemid 40616400)
27. Lien HC, Lu YS, Shun CT, Yao YT, Chang WC, Cheng AL,. 2008. Differential expression of glucocorticoid receptor in carcinomas of the human digestive system. Histopathology 52: 314-324.
28. Lofstedt T, Jogi A, Sigvardsson M, Gradin K, Poellinger L, Pahlman S, Axelson H,. 2004. Induction of ID2 expression by hypoxia-inducible factor-1: A role in dedifferentiation of hypoxic neuroblastoma cells. J Biol Chem 279: 39223-39231. (Pubitemid 39258183)
29. Lu YS, Lien HC, Yeh PY, Kuo SH, Chang WC, Kuo ML, Cheng AL,. 2006. Glucocorticoid receptor expression in advanced non-small cell lung cancer: Clinicopathological correlation and in vitro effect of glucocorticoid on cell growth and chemosensitivity. Lung Cancer 53: 303-310.
30. Marenholz I, Heizmann CW, Fritz G,. 2004. S100 proteins in mouse and man: From evolution to function and pathology (including an update of the nomenclature). Biochem Biophys Res Commun 322: 1111-1122. (Pubitemid 39164640)
31. Mattern J, Buchler MW, Herr I,. 2007. Cell cycle arrest by glucocorticoids may protect normal tissue and solid tumors from cancer therapy. Cancer Biol Ther 6: 1345-1354. (Pubitemid 351590341)
32. Matthews L, Berry A, Ohanian V, Ohanian J, Garside H, Ray D,. 2008. Caveolin mediates rapid glucocorticoid effects and couples glucocorticoid action to the antiproliferative program. Mol Endocrinol 22: 1320-1330. (Pubitemid 351786993)
33. Mirzoeva OK, Das D, Heiser LM, Bhattacharya S, Siwak D, Gendelman R, Bayani N, Wang NJ, Neve RM, Guan Y, Hu Z, Knight Z, Feiler HS, Gascard P, Parvin B, Spellman PT, Shokat KM, Wyrobek AJ, Bissell MJ, McCormick F, Kuo WL, Mills GB, Gray JW, Korn WM,. 2009. Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res 69: 565-572.
34. Moutsatsou P, Papavassiliou AG,. 2008. The glucocorticoid receptor signalling in breast cancer. J Cell Mol Med 12: 145-163.
35. Namba T, Homan T, Nishimura T, Mima S, Hoshino T, Mizushima T,. 2009. Up-regulation of S100P expression by non-steroidal anti-inflammatory drugs and its role in anti-tumorigenic effects. J Biol Chem 284: 4158-4167.
36. Necela BM, Cidlowski JA,. 2004. Mechanisms of glucocorticoid receptor action in noninflammatory and inflammatory cells. Proc Am Thorac Soc 1: 239-246.
37. Onda K, Nagashima M, Kawakubo Y, Inoue S, Hirano T, Oka K,. 2006. Mitogen-activated protein kinase kinase 1/extracellular signal-regulated kinase (MEK-1/ERK) inhibitors sensitize reduced glucocorticoid response mediated by TNFalpha in human epidermal keratinocytes (HaCaT). Biochem Biophys Res Commun 351: 266-272. (Pubitemid 44635436)
38. Parkkila S, Pan PW, Ward A, Gibadulinova A, Oveckova I, Pastorekova S, Pastorek J, Martinez AR, Helin HO, Isola J,. 2008. The calcium-binding protein S100P in normal and malignant human tissues. BMC Clin Pathol 8: 2.
39. Saklatvala J,. 2002. Glucocorticoids: Do we know how they work ? Arthritis Res 4: 146-150. (Pubitemid 34460751)
40. Santamaria-Kisiel L, Rintala-Dempsey AC, Shaw GS,. 2006. Calcium-dependent and -independent interactions of the S100 protein family. Biochem J 396: 201-214. (Pubitemid 43837235)
41. Song J, Shih Ie M, Chan DW, Zhang Z,. 2009. Suppression of annexin A11 in ovarian cancer: Implications in chemoresistance. Neoplasia 11: 605-614 1 p following 614.
42. Spies CM, Schaumann DH, Berki T, Mayer K, Jakstadt M, Huscher D, Wunder C, Burmester GR, Radbruch A, Lauster R, Scheffold A, Buttgereit F,. 2006. Membrane glucocorticoid receptors are down regulated by glucocorticoids in patients with systemic lupus erythematosus and use a caveolin-1-independent expression pathway. Ann Rheum Dis 65: 1139-1146. (Pubitemid 44277386)
43. Sun HW, Miao CY, Liu L, Zhou J, Su DF, Wang YX, Jiang CL,. 2006. Rapid inhibitory effect of glucocorticoids on airway smooth muscle contractions in guinea pigs. Steroids 71: 154-159. (Pubitemid 43087739)
44. Surowiak P, Maciejczyk A, Materna V, Drag-Zalesinska M, Wojnar A, Pudelko M, Kedzia W, Spaczynski M, Dietel M, Zabel M, Lage H,. 2007. Unfavourable prognostic significance of S100P expression in ovarian cancers. Histopathology 51: 125-128. (Pubitemid 46976362)
45. Takabe S, Mochizuki K, Goda T,. 2008. De-phosphorylation of GR at Ser203 in nuclei associates with GR nuclear translocation and GLUT5 gene expression in Caco-2 cells. Arch Biochem Biophys 475: 1-6.
46. Wang G, Platt-Higgins A, Carroll J, de Silva Rudland S, Winstanley J, Barraclough R, Rudland PS,. 2006. Induction of metastasis by S100P in a rat mammary model and its association with poor survival of breast cancer patients. Cancer Res 66: 1199-1207. (Pubitemid 43165991)
47. Wang JC, Derynck MK, Nonaka DF, Khodabakhsh DB, Haqq C, Yamamoto KR,. 2004. Chromatin immunoprecipitation (ChIP) scanning identifies primary glucocorticoid receptor target genes. Proc Natl Acad Sci USA 101: 15603-15608. (Pubitemid 39473534)
48. Watts RG, Huang C, Young MR, Li JJ, Dong Z, Pennie WD, Colburn NH,. 1998. Expression of dominant negative Erk2 inhibits AP-1 transactivation and neoplastic transformation. Oncogene 17: 3493-3498. (Pubitemid 29050684)
49. Wu W, Pew T, Zou M, Pang D, Conzen SD,. 2005. Glucocorticoid receptor-induced MAPK phosphatase-1 (MPK-1) expression inhibits paclitaxel-associated MAPK activation and contributes to breast cancer cell survival. J Biol Chem 280: 4117-4124. (Pubitemid 40288576)